Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02427191 · ClinicalTrials.gov registry record · Phase 2
Micronized dHACM Injectable for the Treatment of Plantar Fasciitis
A Phase 2 study of Fasciitis, Plantar, sponsored by MiMedx Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 147
- Enrollment target
- 11
- Study locations
NCT02427191 is a Phase 2 study of Fasciitis, Plantar that has completed, run by MiMedx Group. The registered enrollment target is 147 participants. The trial reports 11 study locations across 8 states.
The verdict
NCT02427191, a Phase 2 study of Fasciitis, Plantar, has completed, sponsored by MiMedx Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 147 participants
- Enrollment target
- 11
- Study locations
Study Summary
Prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
Conditions Studied
Interventions
- DRUG Saline Injection
- OTHER AmnioFix® Injectable
Study Locations (11)
California
- Limb Preservation Platform, Inc. - Fresno
- Center for Clinical Research, Inc. - San Francisco
Illinois
- Edward Hines Jr. Veterans Administration Hospital - Chicago
- James A. Lovell Federal Health Care Center - North Chicago
Maryland
- Timonium Foot and Ankle Center - Baltimore
- MedStar Union Memorial Hospital - Baltimore
Arizona
- Southern Arizona VA Health Care System - Tucson
Florida
- Orlando VA Healthcare System - Orlando
South Carolina
- WJB Dorn VA Medical Center - Columbia
Texas
- Scott & White Healthcare - Temple
Virginia
- Coastal Podiatry Group - Virginia Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 147 participants |
| Start Date | 2015-03-31 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02427191
The ClinicalTrials.gov registry entry for NCT02427191 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 147 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MiMedx Group, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Fasciitis, Plantar appearing as the primary indexed condition, and to 2 interventions - of which Saline Injection is the first listed.
NCT02427191 reports 11 study locations spanning 8 distinct geographic areas - top geographies include California, Illinois, Maryland.
Frequently Asked Questions
What is clinical trial NCT02427191 about?
NCT02427191 is a clinical study titled "Micronized dHACM Injectable for the Treatment of Plantar Fasciitis". Prospective, single-blinded, randomized controlled trial of the micronized dHACM injection as compared to the saline placebo injection in the treatment of plantar fasciitis
What is the current status of trial NCT02427191?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 147 participants. The study started on 2015-03-31. Estimated completion is 2018-08.
What conditions does trial NCT02427191 study?
This clinical trial studies the following conditions: Fasciitis, Plantar.
What interventions are being tested in trial NCT02427191?
The interventions under investigation include: Saline Injection (DRUG), AmnioFix® Injectable (OTHER).
Who is sponsoring clinical trial NCT02427191?
This trial is sponsored by MiMedx Group, which has 32 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02427191 being conducted?
This trial has 11 study locations across Arizona, California, Florida, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.